Upexi sees 2023 revenue exceeding $100M

Upexi is providing shareholders with a corporate update and is increasing previously announced revenue guidance for full year 2023 to exceed $100 million. Management will be providing shareholders with a specific revenue guidance range during its fiscal 2023 financial results conference call in mid to late-September. Upexi CEO Allan Marshall stated, “We continue to execute and grow our business segments including Vitamedica, Tytan Tiles, and Lucky Tail. Management remains confident in its ability to exceed previously announced 2023 guidance. As the Company’s current valuation does not, in managements’ opinion, reflect the underlying value of our current assets, management and the Board will explore all options to recognize short- and long-term value for shareholders. The Company intends to make an investment in the core business segment which includes our White and Private label businesses. We anticipate that the foregoing business segment will increase our overall revenues and contribute to our overall Adjusted EBITDA. We intend to operate and look to grow this segment of the business as we have done successfully in the past, while continuing to seek strategic options for sale and value creation.”